Jade Biosciences (JBIO) investor relations material

Strategic focus and pipeline overview

• Advancing three potentially best-in-class monoclonal antibody therapies targeting autoimmune diseases, with a focus on infrequent, patient-friendly dosing.

• Lead programs: JADE101 (anti-APRIL for IgA nephropathy), JADE201 (anti-BAFF-R for systemic autoimmune diseases), and JADE301 (anti-IFN-β for dermatomyositis).

• Well-funded with cash runway into Q4 2028, supporting multiple upcoming clinical milestones.

• Exclusive license agreements in place for all three candidates.

JADE101: IgA nephropathy program

• IgAN represents a $20B+ U.S. market with over 169,000 patients, most requiring lifelong treatment.

• JADE101 is a fully human, ultra-high affinity anti-APRIL mAb with extended half-life, enabling dosing as infrequently as every 12 weeks.

• Phase 1 data show ~70% IgA reduction sustained for 12 weeks, favorable safety, and well-tolerated profile.

• Phase 2 trial in IgAN patients initiated; interim data expected in 2027, with Phase 3 planned for 1H 2027.

JADE201: Systemic autoimmune disease program

• JADE201 is an afucosylated anti-BAFF-R mAb with dual mechanism for deep, durable B cell depletion.

• Preclinical studies show high binding affinity, potent ADCC, and extended half-life for less frequent dosing.

• First-in-human Phase 1 trial in rheumatoid arthritis underway; interim data expected in 2027.

• Broad potential across multiple B cell-driven autoimmune indications, including Sjögren's, lupus nephritis, and vasculitis.